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1. Introduction 
Serotonin syndrome is a neurological disorder primarily associated with inappropriate uses 
of serotonin (5HT)-promoting drugs such as serotonin reuptake inhibitors (SRIs), 
monoamine oxidase inhibitors (MAOIs) or 3,4-Methylenedioxymethamphetamine (MDMA; 
Ecstasy) (Boyer et al., 2005; Karunatilake et al., 2006; Parrott, 2002; Paruchuri et al., 2006). The 
primary cause of the syndrome is due to a global increase in brain 5HT that can potentially 
activate all 14 subtypes of 5HT receptors (5HTRs). However, the significance of a given 
subtype contributing to the syndrome is not always the same, depending on the amount of 
5HT evoked by drugs, physical condition of individual patients and even surrounding 
environment of drug administration. As a result, signs and symptoms of the syndrome vary 
widely (Mills, 1995) and thus it has been a clinical challenge to get an accurate diagnosis. 
Regardless, it has been recognized since the early 1990’s that the symptoms of the syndrome 
can be generally classified into 3 categories: mental state changes (mood swings), 
neuromuscular hyperactivity and autonomic dysfunction (Sternbach, 1991). Among these, 
neuromuscular and autonomic symptoms can be replicated in laboratory animals with 
MAOIs combined with 5HT precursors (Shioda et al., 2004) or by MDMA at a high dose 
(Baumann et al., 2008a; Spanos et al., 1989). Thus, despite many difficulties in clinical 
research, there are some great advances in understanding serotonin syndrome thanks 
primarily to preclinical investigation in animals.  
Increasingly, the term “serotonin toxicity” has been used interchangeably with “serotonin 
syndrome”, particularly in MDMA-related research. This is mainly because MDMA at high 
doses could cause a reduction in 5HT content in the brain and possibly axonal degeneration 
(Bhide et al., 2009; Malberg et al., 1998). In fact, there is no evidence indicating that clinically 
relevant doses of MDMA could produce such effects or neural death although symptoms of 
the serotonin syndrome occur [details reviewed by (Baumann et al., 2007)]. For these 
reasons, we avoided using the term “toxicity” in this study unless more relevant 
information such as levels of cell death is available in clinically relevant literature. 
To address the neurological mechanisms underlying the cause of the serotonin syndrome, 
we will review recent research findings on how brain 5HT is dynamically altered following 
administration of 5HT-promoting drugs by which the syndrome would potentially be 
evoked. We will focus on preclinical data since most experimental studies have been carried 
out in rodents (rats and mice). If available, human data will also be included for comparison. 
Additionally, the role of 5HT receptors in the syndrome will be discussed. 
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2. Dynamic changes in 5HT concentration 
Despite the fact that brain 5HT can be found in both the extracellular space and intracellular 
compartments, extracellular 5HT (5HText) is the one involved in neurotransmission in the 
brain. Therefore, first of all, we will review literature on 5HText concentration which, in 
normal physiological condition, likely reflects the functional activity of serotonergic 
neurons. While an exhaustive literature review is not possible here, representative findings 
will be mentioned. For comparison, data related to the level of intracellular 5HT (non-
functional component) will also be included. Pharmacologically, 5HT-promoting drugs 
could elevate 5HText to a particular level resulting in improvement of behavioral response 
and enhancement of mood without causing mental impairment. Thus in the second part we 
will review literature concerning the 5HText level at which behavioral incompetence can be 
improved in response to 5HT-promoting drugs. Thirdly, we will seek evidence of the upper 
limit level (threshold) above which 5HText is too high in the brain and potentially causes 
serotonin syndrome. 
2.1 Normal extracellular concentration 
As a neurotransmitter, 5-hydroxytryptamine (5HT; serotonin) is synthesized mainly at 
serotonergic axon terminals through decarboxylation of 5-hydroxytryptophan (5HTP). 
Newly synthesized 5HT molecules have three possible fates as follows:  
1. uptaken into vesicles by the vesicular monoamine transporter-2 (VMAT2);  
2. oxidized by mitochondrial monoamine oxidase-A (MAOA) followed by aldehyde 
dehydrogenase into 5-hydroxyindoleacetic acid (5HIAA);  
3. spontaneously released into the extracellular space through reverse transporters (Gobbi 
et al., 1993).  
However, newly synthesized 5HT molecules are not randomly or equally directed into these 
three pathways. Their direction depends on physical states and drug action properties in 
medication. Normally, almost all newly synthesized 5HT molecules are uptaken into 
vesicles against concentration gradients. Although little is known about mammalian 
vesicular 5HT concentrations, it is suggested that there may be 270 mM (or 1.6 x 1023 
molecules)  in a 5HT vesicle of leech Retzius neurons (Bruns et al., 1995; Bruns et al., 2000). 
Generally in the brain, over 99% of 5HT molecules are stored in the synaptic vesicles. The 
amount of intracellular 5HT can be estimated using homogenized brain tissue. However, it 
should be kept in mind that the measures likely mirror intensity of serotonergic 
innervations (Schaefer et al., 2008), but not functional activity of neurotransmission. 
Nevertheless, the range of 5HT content in the homogenized brain is 1 to 2 nmol/g 
(Baumann et al., 2008a; Bhide et al., 2009; Grahame-Smith et al., 1974; Malberg et al., 1998). 
Moreover, raphe nuclei have relatively higher contents than other regions (Adell et al., 
1991b). A similar range is also found in the mouse brain (Kim et al., 2005; Pothakos et al., 
2010).  
Several studies have been carried out to measure 5HT content in the post-mortem human 
brain (Parsons et al., 1992; Seidl et al., 1999). In general, 5HT is in the range of 100-400 
pmol/g in homogenized tissues. Since 5HT is rapidly oxidized in the post-mortem tissues, it 
is likely that the level in the human brain is underestimated.  
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5HText is considered to be critical in maintaining mood and other affective functioning, 
although normally its quantity is estimated to be less than 0.1% of total 5HT molecules in 
the brain. At such an exceptionally small quantity, it is a challenge to determine its level in 
the human brain. Indeed, a PubMed search indicates that there are no relevant data 
available in clinical literature. Despite this, highly sensitive approaches have been 
developed during the last two decades for laboratory animals. For instance, Adell et al. 
measured 5HText in the cerebrospinal fluid using conventional microdialysis in the frontal 
cortex, striatum, hypothalamus, hippocampus, inferior colliculus and raphe nuclei, 
demonstrating that the 5HText concentration is in the range of 0.5-2 nM (Adell et al., 1991b). 
Thus, it appears that 5HText in the rat cerebrospinal fluid is at a low nanomolar level. The 
same conclusion has been obtained by other studies with rats and mice using zero-net-flux 
microdialysis (Calcagno et al., 2007; Gardier et al., 2003; Mathews et al., 2004; Tao et al., 2000). 
The amount and distribution of 5HT into the extracellular space are strongly implicated in 
many mental health problems. Physiologically, the concentration of 5HText is constantly kept 
at a state of equilibrium, involving balanced regulation between spontaneous release, 
5HT1AR feedback inhibition and reuptake mechanisms as demonstrated in in vitro and in 
vivo studies (Becquet et al., 1990; Blier, 2001; Sharp et al., 2007; Wolf et al., 1986). On the other 
hand, the intracellular concentration in vesicles of serotonergic terminals is at a high 
milimolar (mM) level, implying that intracellular 5HT can rapidly elevate 5HText to an 
extraordinary level in response to 5HT-promoting drugs. The response scale can be widely 
variable, ranging from a several-fold to a hundred-fold increase (Rutter et al., 1995; Shioda et 
al., 2004; Zhang et al., 2009). Neuropharmacological investigations into the level of increased 
5HText in response to 5HT-promoting drugs will be highlighted in the next section. 
2.2 Therapeutic elevation of 5HText by 5HT-promoting drugs 
Many psychoactive drugs used for patients are able to elevate 5HText in the brain. To better 
elucidate the neuropharmacological range of extracellular concentrations, we focus on three 
categories of 5HT-promoting drugs: serotonin reuptake inhibitors (SRIs), monoamine 
oxidase inhibitors (MAOIs) and 5-hydroxyl-L-tryptophan (5HTP). SRIs, which elevate 
5HText by blocking 5HT from reentering synapses, have been widely prescribed for decades 
in the treatment for depression, anxiety and posttraumatic stress disorders. MAOIs are one 
of the oldest classes of antidepressants, functioning by increasing extravesicular 
accumulation and spontaneous release. 5HTP is the immediate precursor compound for 
5HT synthesis, which is considered to be an important supplemental ingredient in 
promoting mood (Parker et al., 2011). Altogether, 5HText elevation is a part of critical 
mechanisms in the course of medical treatment for some mental diseases although other 
mechanisms based on 5HT receptors and relevant intracellular signaling pathways are also 
involved (Sharp et al., 2011). Up to date, laboratory methods for determining 5HT release in 
patients’ brain are not available and thus how much elevation of 5HText is sufficient to 
improve mental health in humans is unknown. The relevant knowledge on the 
neurochemical effects of these drugs is almost exclusively obtained by animal studies.  
There are several members in the SRI family, mainly (but not exhaustively) comprising 
selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors 
(SNRIs) and tricyclic antidepressants (TCAs). For the last three decades a variety of 
approaches and treatment protocols have been examined on animals to investigate how 
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these drugs act against 5HT reuptake into serotonergic neurons in the brain. It appears that 
acute systemic injection could cause only a regionally selective increase in 5HText (Beyer et 
al., 2008; David et al., 2003; Rutter et al., 1993). At clinically relevant doses, the maximum 
elevation evoked by SRIs is relatively low, at less than a 2-fold increase over baseline. This is 
because a global increase in 5HText by systemic injection would activate autoreceptors, 
namely 5HT1ARs in the raphe that inhibit discharge-dependent release of 5HT at axon 
terminals, limiting further increase in 5HText  (Hervas et al., 2000; Rutter et al., 1995). Related 
to this, 5HT1AR activation is associated with an acute anxiogenic response to SRIs, examined 
with laboratory animals (Birkett et al., 2011; Greenwood et al., 2008). Indeed, SRIs are known 
to have an anxiogenic effect in human patients, particularly during the early period of 
medical treatments (Bigos et al., 2008; Browning et al., 2007). 
Functional activity of 5HT1ARs can be to some extent desensitized after long-term use of 
SRIs (Blier, 2001; El Mansari et al., 2005). As a result, 5HText elevation is slightly augmented, 
most likely to around 2-3 fold (Dawson et al., 2000) but never more than 5-fold (Popa et al., 
2010). It has been hypothesized that the desensitized 5HT1ARs together with increased 
5HText, but neither alone, are two required elements for antidepressant treatments (Sharp et 
al., 2011). If the hypothesis were correct, it suggests that a less than 5-fold increase in 5HText 
in the cerebrospinal fluid is sufficient for therapeutic purposes. 
In addition to 5HT1ARs, other 5HTR subtypes could also affect the profile of SRIs, thereby 
affecting 5HText elevation (Cremers et al., 2007; Jongsma et al., 2005). This suggests that in the 
brain there exist several other feedback loops that collectively influence the effect of 
systemic administration of SRIs. In other words, the response to SRIs would be stronger 
after eliminating the feedback inhibition. Consistently, the 5HText response is much higher 
when the drug administration is locally applied in the brain (Adell et al., 1991a; Hervas et al., 
2000; Tao et al., 2000). The maximum elevation of 5HText by local application of SRIs can be 
5-fold but less than 10-fold compared to the baseline. Although 5HText at this level appears 
to be higher than normal, there is no evidence in the literature suggesting that a 5 to 9-fold 
increase is associated with mental impairment such as serotonin syndrome. 
It should be kept in mind that 5HT reuptake is one of the important pathways for 5HT 
metabolism. Drugs that have an effect on the reuptake would likely pose the risk of 
interrupting the integrity of 5HT metabolism, particularly after long-term use (Moret et al., 
1992; Stenfors et al., 2001). It has been shown that chronic treatment with SRIs could reduce 
the amount of intracellular 5HT in some brain regions (Bianchi et al., 2002).Whether the 
reduced 5HT content would ultimately affect the SRI-evoked increase in 5HText, or whether 
such chronic effects on intracellular 5HT are associated with the development of treatment 
resistance in patients is not clear.  
MAOIs are a family of drugs that inhibit the activity of the MAO-A isozyme located at the 
outer membrane of mitochondria in the synapses of serotonergic axon terminals, causing 
5HT accumulation in the cytoplasmic compartment (Evrard et al., 2002; Ferrer et al., 1994). 
Since the capacity of the cytoplasm to retain 5HT molecules is very limited while the 
synaptic vesicles are full, the only place for the extravesicular 5HT is to “spillover” into the 
extracellular space. The mechanisms for 5HT spill are not fully elucidated, most likely 
through the transmitter carriers that reversely transport extravesicular 5HT into the 
extracellular space (Gobbi et al., 1993; Silva et al., 2008). Thus, administration of MAOIs 
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would cause an increase in 5HText proportional to that of intracellular content (Ferrer et al., 
1994). Normally, a maximum increase following systemic injection is about 1 to 2-fold above 
baseline (Ferrer et al., 1994; Rollema et al., 2011). The effect of MAOIs is also determined by 
dietary ingredients, particularly of those containing the 5HT precursor such as tryptophan 
and 5HTP.  It deserves separate mention that one of the major side effects in the clinical use 
of the old generation of MAOIs is hypertensive crisis, known as “cheese reaction” due to 
ingestion with tyramine-rich diets. The good news is that the new generation of MAOIs has 
fewer side effects relevant to diet [reviewed by (Wimbiscus et al., 2010)]. Clinically, while 
SRIs are widely used as a first-line drug to treat depression, MAOIs are often recommended 
for treatment-resistant depression. Similar to SRIs, the MAOI-evoked increase in 5HText is 
also regulated by feedback mechanisms involving 5HT1ARs (Lanteri et al., 2009). Hence, like  
SRIs, MAOIs could produce relatively higher increases after the feedback inhibition 
mechanism is eliminated or desensitized, showing a maximum elevation of 5-10 fold above 
baseline (Tao et al., 1994). 
5HTP is recommended as a supplemental treatment for depression and menopausal hot 
flush (Curcio et al., 2005; Shaw et al., 2002). In humans, the typical 5HTP dosage  is 100-300 
mg/day or 1-3 mg/kg [reviewed by (Turner et al., 2006)]. In animals, 5HTP alone has no 
measurable effect on 5HText except at a dose of 40 mg/kg and higher (Gartside et al., 1992; 
Perry et al., 1993). This implies that newly synthesized 5HT molecules can be rapidly 
metabolized before being accumulated in the extravesicular compartment for spontaneous 
release. Specifically, 5HText was increased by 2-fold in response to 75 mg/kg 5HTP 
(Nakatani et al., 2008) and by 4-fold in response to 100 mg/kg 5HTP (Gartside et al., 1992). In 
summary, it appears that 5HTP alone at the dose typically used in human patients has little 
contribution to the level of 5HText.  
2.3 Dangerous elevations of 5HText: How much 5HText in the CNS is too much? 
There is no doubt that 5HText is tightly regulated as a part of a homeostasis, most likely 
remaining at a low nanomolar concentration for maintaining normal brain function. 
Hypothetically, 5HText in patients with major depression is too low to stimulate 5HTRs for 
an affective process (such as mood). 5HT-promoting drugs could lift mood by correcting 
5HText level. The amount of 5HT elevation is still at a small scale when drugs are used alone 
(monopharmacy).  
However, 5HText could be overcorrected, particularly with medication switching and 
polypharmacy. Despite decades of clinical research, no laboratory test is available to 
monitor brain 5HText during a drug regimen in humans. It has been suggested that the 
change in brain 5HText is in parallel with changes in peripheral 5HT or 5HIAA measured in 
blood and urine (Alvarez et al., 1999; Bianchi et al., 2002; Celada et al., 1993). Metabolically, 
peripheral 5HT is however independent of 5HT in the CNS; how changes in peripheral 5HT 
in response to drug treatment can infer changes in the brain is not yet established.  
Although drug treatments would improve the mental well-being scale in terms of 
psychological evaluations, patients are at risk of having “excessive” 5HText in the brain. 
Thus, it is important to determine a safe range of 5HText concentrations for improvement in 
mood without causing excessive 5HText-induced side effects. It has been suggested by in vivo 
microdialysis studies that 5HT-promoting drugs usually produce a nanomolar (nM) level of 
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5HText in the cerebrospinal fluid. However, in vitro studies demonstrate that  a micromolar 
(μM) concentration is required to have postsynaptic effects on 5HTR-containing neurons 
(Cornelisse et al., 2007; Marinelli et al., 2004). This discrepancy in 5HText levels possibly 
represents the difference in microenvironments between the cerebrospinal fluid and 
synapses in the extracellular space. Conceivably, most 5HT molecules released from 
synapses are rapidly taken back by transporters while a small portion is diffused away from 
the synapses. If this is the case, synaptic 5HT concentration must be much higher than that 
in the cerebrospinal fluid measured by microdialysis. In addition, 5HText released from 
synapses is not evenly distributed in vivo across postsynaptic cell membranes. The amount 
of distribution depends on the distance from the release site. The concept of concentration 
differences in microenvironments is also supported by other studies. For instance, utilizing 
fast-scan cyclic voltammetry at a time resolution of 100 msec, it has been observed that 
5HText at the extrasynaptic site was rapidly (~5 s) increased from nM to μM in response to 
electrical stimulation (Bunin et al., 1998). In contrast, comparable stimulations could only 
induce a 1-2 fold increase in 5HText in the cerebrospinal fluid determined by microdialysis at 
intervals of 20 min (McQuade et al., 1997). This suggests that the 5HText concentration in the 
extrasynapse compartment is much higher than in the cerebrospinal fluid, supporting the 
view of microenvironmental variation. Note that such high concentration of 5HText at 
synapses and/or extrasynaptic sites may not cause a neural disorder because: 1) the time 
duration of the effect is usually only a few milliseconds; 2) numbers and types of synaptic 
neurons involved in the action are highly localized; 3) the neurotransmitter can be rapidly 
removed by 5HT reuptake transporters. However, it could be problematic if there are 
prolonged and widespread effects on many 5HTR-containing neurons.   
Except for MDMA, few 5HT-promoting drugs acting alone could elevate 5HT to high levels 
for a long period. This may occur mainly when two or more 5HT metabolic pathways are 
simultaneously disrupted during medication switching or polypharmacy, resulting in 
“excessive” 5HText that exerts an adverse effect on mental health. For instance, Shioda et al. 
investigated the interaction between MAOIs and SSRIs for understanding changes in 5HText 
relevant to serotonin syndrome (Shioda et al., 2004). In their investigation, male Wistar rats 
received co-injection of tranylcypromine (3.5 mg/kg), a nonselective MAOI, and fluoxetine 
(10 mg/kg), an SSRI. Hypothalamic 5HText was determined by microdialysis while serotonin 
syndrome was estimated by measuring body-core temperature and neuromuscular activity. 
The environmental temperature was set at 23 ±1 °C. Under this condition, drug interaction 
caused an increase in 5HText by 40-fold above the pre-drug level, lasting at least 6 hours. 
There were obvious signs of serotonin syndrome including hyperthermia, head shakes and 
tremor, suggesting that 5HText at this level causes both physical and behavioral problems. 
Since each drug alone could only evoke a 2-3 fold increase, it appears that their combined 
effect is not simply additive, but synergistic. Other neurotransmissions, for instance, 
dopaminergic and glutamatergic systems that usually are not affected by single drug 
treatments are also elevated. This suggests that neural circuits consisting of several neuronal 
systems are involved in the syndrome, which is beyond the scope of this analysis and will 
not be discussed further here. 
It is critical to determine the threshold level of 5HText responsible for evoking serotonin 
syndrome. Baumann et al examined the harmful potential of MDMA by scoring behavior 
signs of serotonin syndrome (e.g., flat-body posture and forepaw treading) in correlation 
with elevated 5HText in the frontal cortex and nucleus accumbens of male Sprague-Dawley 
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rats (Baumann et al., 2008a; Baumann et al., 2008b).  In their behavioral and neurochemical 
studies, animals received a first injection of MDMA at the dose of 1 mg/kg followed by a 
second injection of 3 mg/kg 60 min later. The ambient temperature in which animals were 
examined was 22±2 °C. As a result, 5HText was increased by 5- to 8-fold in response to 1 
mg/kg and 18- to 33-fold following 3 mg/kg. While MDMA at 1 mg/kg had no effect on 
animal behavior, 3 mg/kg of MDMA were able to induce symptoms of the serotonin 
syndrome, suggesting that the 5HText threshold to evoke the serotonin syndrome may be in 
a range between 9 to 18-fold. 
Compared to other 5HT-promoting drugs, a single injection of MDMA at clinically relevant 
doses has a transient effect on 5HT, lasting only 15-30 min in terms of peak effect.  To obtain 
a significant response, many investigators employ multiple injections to mimic the binge use 
of MDMA in humans. Theoretically, multiple injections could produce several 5HT peak 
responses which would complicate the elucidation of causal relationships between 5HT and 
behavioral effects. To simplify the analysis, 5HT precursors (e.g., 5HTP) in combination with 
MAOI (e.g., clorgyline) are more applicable for elucidating the 5HT threshold. Many studies 
have demonstrated that a single injection of 5HTP combined with clorgyline was sufficient 
to produce a dose-dependent increase in 5HText in the brain, causing serotonin syndrome 
(Ma et al., 2008; Nisijima et al., 2004; Nisijima et al., 2000; Nisijima et al., 2001; Shioda et al., 
2004). To obtain the threshold level of 5HText, we designed a 5HTP dosing regimen in 
clorgyline-pretreated rats. Male Sprague–Dawley rats were examined under controlled 
ambient temperature (22 ± 1°C) and humidity (70%) in test chambers (Ma et al., 2008; Zhang 
et al., 2009). Animals received 2 mg/kg clorgyline, 2 hours before injection of 5HTP at the 
dose range of 1 to 25 mg/kg. 5HText was determined in the frontal cortex and hypothalamus 
while behavioral responses were recorded with a 4-level scale by scoring the severity of 
tremor, head shakes, forepaw treading, hindlimb abduction, myotonia and Straub tail.  
Specifically, 5HText was potentially elevated to as high as 100-fold above baseline following a 
single injection of 5HTP into clorgyline-pretreated rats, consistent with the results of 
previous studies (Shioda et al., 2004). In fact, this level of 5HText is already well over the 
threshold for inducing a serotonin syndrome. Our data showed that a 55-fold increase in 
5HText caused the severe syndrome manifested by high hyperthermia and all other typical 
signs described in animals (Jacobs et al., 1975) or severe symptoms resembling those 
described in humans (Mills, 1995). An open question is whether such a high 5HText level is 
really evoked in the human brain despite drug interactions.  
Our studies further demonstrated that a 10-fold increase in 5HText was sufficient to cause a 
mild syndrome, showing hypothermia, head shakes and myoclonus but no signs indicative 
of advanced or severe syndrome (e.g., tremor, forepaw treading or hindlimb abduction) (Ma 
et al., 2008; Zhang et al., 2009).  This suggests that the brain is most likely intolerant of the 
double digit increase in 5HText in terms of fold-change in the cerebrospinal fluid.  There was 
no syndrome-related behavioral changes in response to a 5- to 9-fold increase although head 
shakes were still apparent, supporting the conclusion that a single digit increase is highly 
tolerable. The head shaking behavior disappeared when the increased 5HText decreased to 5-
fold and less, consistent with suggestion that a less than 5-fold increase in 5HText in the brain 
is essentially safe. Clearly, more investigation into this important area of research is needed. 
It is crucial to relate changes in behavior to changes in 5HT ext level, particularly after long-
term interactions between 5HT-promoting drugs. 
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3. Involvement of 5HT receptors 
There are at least 14 subtypes of 5HT receptors (5HTRs) in the brain (Green, 2006). One may 
wonder what the role is an individual subtype in the development of the serotonin 
syndrome.  It should be kept in mind that 5HT is the natural agonist for these subtypes in 
the brain; and involvement of individual subtypes depends on not only the availability of 
the agonist but also the binding affinity to the agonist. It has been recognized for many years 
that the strength of 5HT affinity can be widely different. For instance, a μM concentration 
may be required for binding 50% of low affinity 5HT2ARs whereas a nM concentration for 
high affinity 5HT1ARs (Dalpiaz et al., 1995; Peroutka et al., 1981; Peroutka et al., 1983). Thus, 
the role of each subtype in the syndrome is complicated, and depends on multiple factors.  
For better comparison between subtypes, pKd or pKi values are commonly used to indicate 
the strength or the selectivity of ligands to a given subtype. It is worthy pointing out that 
their values are not always reliable or consistent between tests due to variables in 
experimental conditions. Despite this, they provide trends for estimating affinity between 
receptor and ligand. It is well known that affinity values are strongly associated with 
functional activity of receptors in the brain (Clemett et al., 1999; Knight et al., 2004; Rossi et 
al., 2008). Although few studies are available to completely map the affinity between 5HT 
and its receptor subtypes under the same condition, a valuable reference is found from the 
database provided by the International Union of Basic and Clinical Pharmacology or 
IUPHAR (Table 1). Based on their database, the 14 subtypes can be ranked in the order of 
affinity strength from high (sub-nM; or 10-9 M) to low activity (μM or 10-6 M). Although so 
many subtypes are available in the brain, it appears that they are not functioning 
simultaneously. Their neurological function is selectively elicited by 5HT in a concentration-
dependent manner. For instance, 5HT at the concentration of approximately 10-9 M could 
competitively displace 50% of competitors at the 5HT1AR site, implying that a sub-nM 
concentration is able to activate 5HT1ARs. In support of this, as demonstrated in vitro in 
dorsal raphe slices, the inward current indicative of 5HT1AR activity can be elicited by 5HT 
at concentration less than 1 nM with the EC50 at 30 nM (Penington et al., 1993), closely in line 
with results obtained by radioligand binding assays. By contrast, other subtypes such as 
5HT2ARs are unlikely to be affected by 5HT at such a low concentration. It should be noted 
that 5HT1ARs are densely located on the somatodendritic sites of serotonergic neurons in the 
raphe (Li et al., 1997) and their high binding affinity to 5HT is physiologically important for 
their role in negative feedback regulation.  
5HT1ARs are also distributed on many types of postsynaptic neurons (Bert et al., 2006), 
particularly glutamatergic and GABAergic neurons in the cortices (de Almeida et al., 2008; 
Martin-Ruiz et al., 2001). It has often been shown that these postsynaptic 5HT1ARs can be 
activated by 5HT at a relatively high concentration between 1-10 μM (Goodfellow et al., 
2009; Schmitz et al., 1998), controlling the functional balance between glutamate and GABA 
transmissions.  
Thus, since 5HText in response to most psychoactive drugs is normally in a nanomolar range 
(Gardier et al., 2003), these postsynaptic receptors are unlikely to be able to be activated. In 
the case of 5HText exceeding maximum tolerable limits, there is a global activation of 
postsynaptic 5HT1ARs, causing fluctuation of GABA and glutamate, two functionally 
opposite neurotransmitters. It is likely that this fluctuation in the CNS is responsible for 
neuromuscular hyperactivity (Paterson et al., 2009), but verification of this hypothesis 
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related to the serotonin syndrome involving head weaving, tremor and forepaw treading 
awaits for further investigation.  
 
5HT1AR 9.1 – 9.7 
5HT7R 8.1 – 9.6 
5HT1DR 8.0 – 9.0 
5ht1eR 8.0 – 8.2 
5HT2BR 7.9 - 8.4 
5HT1FR 7.7 – 8.0 
5HT1BR 7.4 – 9.0 
5HT2CR 6.8 – 8.6 
5HT6R 6.8 – 7.5 
5ht5aR 6.7 – 6.9 
5HT3AR 6.5 – 6.9 
5HT2AR 6.0 – 8.4 
5HT3ABR 6.0 
5HT4R 5.9 – 7.0 
Data from the database provided by the International Union of Basic and Clinical Pharmacology or 
IUPHAR (http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?familyId=1&objectId=1) 
Table 1. 5HT binding affinity (pKi) 
Based on 5HText concentration, we suggest that the 5HT subtypes can be hypothetically 
classified into 5 groups: sub-nM, nM, high nM, sub-μM and μM. As elucidated in Table 2, 
more and more subtypes in the brain are involved when the concentration is increased. It is 
likely that, as 5HText exceeds its upper tolerable level, lower affinity subtypes are activated 
along with higher affinity ones.  
 
5HText 
levels 
Sub-nM nM High nM Sub-μM μM 
Affected 
receptors 
5HT1AR 
(presynaptic)
 5HT7R 
5HT1AR 
(presynaptic)
5HT7R 
5HT2BR 
5ht1eR 
5HT1DR 
 
5HT1AR 
(presynaptic) 
5HT7R 
5HT2BR 
5ht1eR 
5HT1DR 
5HT1BR 
5HT1FR  
5HT1AR (pre-
postsynaptic) 
5HT7R 
5HT2BR 
5ht1eR 
5HT1DR 
5HT1BR 
5HT1FR 
5HT2CR 
5HT6R   
5ht5aR 
5HT3AR 
5HT1AR (pre- 
postsynaptic)  
HT7R 
5HT2BR 
5ht1eR 
5HT1DR 
5HT1BR 
5HT1FR 
5HT2CR 
5HT6R   
5ht5aR 
5HT3AR 
5HT2AR 
5HT4R 
5HT3ABR 
Table 2. Neurological relationship between subtype activation and increased 5HText. More 
and more subtypes are activated as 5HText levels are increased from sub-nM to μM 
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Using a radioligand receptor binding assay, studies have shown that 5HT2ARs have low 
affinity and are not easily bound to 5HT (Peroutka et al., 1981; Peroutka et al., 1983). The 
significance of this finding has not been recognized simply because the threshold level of 
5HText concentration in maintaining mental health is not fully appreciated. 5HT2ARs are 
mainly (but not exclusively) distributed on glutamatergic neurons in the cortices (de 
Almeida et al., 2007) and are critical for regulating the interconnection between the cortex 
and raphe. It has been widely documented in in vitro studies that 5HT2ARs cannot be 
activated until the 5HT concentration reaches 20-50 μM (Aghajanian et al., 1997; Zhou et al., 
1999), suggesting that their activation threshold is much higher than 5HT1ARs. Importantly, 
the answer to whether 5HT2ARs are involved in the syndrome is a life-or-death issue. This is 
mainly because 5HT2ARs are the major receptor strongly associated with hyperthermia and 
other autonomic hyperactivity (Mazzola-Pomietto et al., 1995; Zhang et al., 2011). 
Hyperthermia is believed to be the major cause for severe brain injury as demonstrated by 
MDMA studies (Malberg et al., 1998). Collectively, the serotonin syndrome resulting from 
activation of 5HT1ARs and 5HT2ARs is associated with excessive 5HText up to a single to 
double-digit μM concentration at synapses. This suggests that 5HText in the synapse has 
arisen by 1000 times while it usually remains at a low nanomolar level. The effect is likely to 
correspond to a double-digit fold increase in the cerebrospinal fluid measured by in vivo 
microdialysis (Zhang et al., 2009).  
Most recent data have revealed that the functional activity of some 5HTR subtypes can be 
altered by environmental factors (Krishnamoorthy et al., 2010; Nicholas et al., 2003; Zhang et 
al., 2011). For instance, Nicholas et al demonstrated that, compared to a normal experimental 
condition, 5HT1AR activity was markedly reduced in animals examined in warm ambient 
temperatures. On the other hand, the responsivity of 5HT2ARs could be markedly enhanced 
in warmer environments (Zhang et al., 2011). Similarly, it has been found in an in vitro 
binding kinetic assay that 5HT affinity to 5HT2ARs was strongly increased in a temperature-
dependent manner (Dalpiaz et al., 1995). Taken together, 5HText concentration required for 
activation of 5HTRs may vary. Indeed, it has been observed that serotonin syndrome 
evoked by MDMA and other 5HT-promoting drugs is severely augmented in hot and 
crowded conditions at raves and dance clubs (Parrott, 2002) but ameliorated in a cooling 
environment (Krishnamoorthy et al., 2010). 
4. Summary 
The aim of this review is to elucidate possible ranges of brain 5HText in association with 
therapeutic benefit, tolerable side effects and the development of serotonin syndrome. 
5HText is derived from either spontaneous release or active stimulation, which initially 
presents at synapses and subsequently diffuses into the cerebrospinal fluid. In contrast to 
5HT at synapses, 5HText in the cerebrospinal fluid can be easily determined by microdialysis. 
Physiologically, a low nanomalor concentration (nM) is crucial for normal function of 
maintaining constant activation of postsynaptic 5HTRs.  In the case of depression, 5HText is 
at a lower level, resulting in reduced activity of 5HTRs that can affect mood and behaviors. 
An appropriate elevation of 5HText promotes a positive mood and an energized sense of 
physical well-being.  Therapeutically, 5HText elevated by 5HT-promoting drugs such as SRIs 
or MAOIs up to 5-fold in the cerebrospinal fluid is sufficient to improve the mood. 
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Unfortunately, MDMA (‘Ecstasy”) hijacks such positive aspects of the serotonergic effect, 
causing drug abuse. Although generally safe, 5HT-promoting drugs could evoke an increase 
in 5HText in the cerebrospinal fluid exceeding 10-fold. When it occurs, the 5HText level in the 
synapses most likely reaches a single to double-digit μM concentration, which would 
globally activate 5HT1ARs and/or 5HT2ARs on glutamatergic and GABAergic neurons. Such 
global activation involved in both glutamate and GABA transmission leads to neurological 
disorders, which are manifested as serotonin syndrome. Importantly, the actions of 5HText 
on 5HTRs are highly variable, and strongly depend on behavioral states as well as external 
environments. Thus, the severity of the syndrome can vary from mild, to moderate, to life-
threatening (Krishnamoorthy et al., 2010; Parrott, 2002). 
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